Ask Me Anything ALS
The I AM ALS’ “Ask Me Anything ALS” series consists of community-led conversations where people living with and impacted by ALS come together to share their experience and answer questions about a specific topic.
These conversations are open to any interested person and take place between people who have lived experiences with the specific topic and others from the ALS community. We learned from the community the importance of connecting with and learning from others in similar situations, which is exactly what these events intend to do – make connections and share resources! Attendees can submit questions ahead of time when signing up, join to ask additional questions, or simply listen and learn.
- Finding Meaning and Purpose
- PEG & Nutrition
Here’s a complete list of topics we’ve covered in this series, as well as any videos or resources that came from each event. The entire Youtube playlist can be found here.
- How/Why I Joined I AM ALS
- Familial ALS – hosted by the Familial ALS Team
- Tracheostomies (Part 1 and Part 2)
- Raising Kids While Impacted by ALS
- Veterans – hosted by the Veterans Team
- Addressing ALS Communication Challenges
- ALS Communication Technology (Part 1 and Part 2)
- Caring for a Parent
Want to hear from the ALS community about a topic not listed above? Suggest a topic for a future Ask Me Anything ALS event! If you have a suggestion, please reach out to us on our Contact Us page here.
We will find cures for ALS. The only question is when. That answer depends on you.
Stay informed on I AM ALS’ progress and what you can do to help us make hope real.
NINDS has awarded the first Expanded Access Grant under ACT for ALS
Today, September 30, 2022, the National Institute of Neurological Disorders and Stroke (NINDS) awarded the first of what we hope to be many Expanded Access Program (EAP) grants to help people with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for clinical trials.
I AM ALS statement regarding 7 – 2 vote in favor of AMX0035 approval
On September 7, 2022, the Peripheral and Central Nervous System Drugs Advisory Committee (AdCom) met for the second time to discuss the New Drug Application (NDA) for AMX0035. After hearing from clinicians, scientists, field experts, and people living with ALS, the committee voted 7 - 2 in favor of approval!